First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs)
July 2019
Merkul et al. Expert Opinion on Drug Delivery. In press (accepted 15 July 2019).
In this peer-reviewed paper, we summarize all advantages that our platinum-based Lx® linker technology holds for the development and manufacturing of antibody-drug conjugates. Our Lx®-based lead ADC outperforms all benchmarks whilst displaying a favorable safety profile, at least in part due to outstanding in vivo stability. In addition, Lx® technology enables highly cost-efficient manufacturing in a very simple plug-and-play manufacturing process. We believe that Lx® technology will enable the creation of ADCs that are effective, safe and affordable.